Background Lung adenocarcinoma (LUAD), the most prevalent form of nonsmall cell lung cancer, poses significant diagnostic and therapeutic challenges due to its high mortality rate and complex pathophysiology. Despite advances in understanding LUAD’s molecular underpinnings, existing biomarkers are insufficient for personalized treatment, highlighting a critical need for innovative diagnostic and prognostic tools. Method By systematically analyzing data from the TCGA database, we identified three distinct metabolic subtypes of LUAD and conducted in‐depth metabolic and immune profiling on these metabolic subtypes. This study employs extensive bioinformatics methodologies, including weighted gene co‐expression network analysis (WGCNA) and least absolute shrinkage and selection operator (LASSO) regression, to discover and validate key genetic markers that impact LUAD prognosis. Results Our findings indicate that specific genes, such as SELK, C4orf27, PRDM2, FOSL2, and CHCHD4, play crucial roles in LUAD progression by intricately regulating ubiquitination pathways vital to tumor behavior. These genes are instrumental in orchestrating the delicate balance between ubiquitination and deubiquitination, essential for maintaining cellular homeostasis and regulating protein degradation pathways critical in oncogenesis. Notably, these genes exhibit a strong correlation with poor survival outcomes, highlighting their potential as therapeutic targets. Conclusions The unique value of this research lies in the novel integration of metabolic, immune, and genomic data to elucidate LUAD’s heterogeneity. By pinpointing critical genetic drivers of LUAD and their broader biological impacts, this study significantly enhances our capability to predict and alter the disease’s trajectory, ultimately paving the way for advancements in targeted therapies.
Yang et al. (Thu,) studied this question.